Skip to main content
Premium Trial:

Request an Annual Quote

Danaher Reaffirms 2012 Guidance, Provides 2013 Estimate

NEW YORK (GenomeWeb News) – Danaher has reaffirmed its net earnings guidance for the fourth quarter and full-year 2012 and provided 2013 guidance in advance of its investor meeting to be held today.

The Washington, DC-based conglomerate, which purchased Beckman Coulter last year, said that it expects to report Q4 earnings-per-share from continuing operations of $.80 to $.85. It expects its full-year net earnings to be $3.14 to $3.19. The consensus Wall Street estimate for the fourth quarter is $.83 and for the full year is $3.16.

Danaher also said it anticipates its FY 2013 net earnings to be between $3.40 and $3.55. That guidance assumes core revenue growth of between 1 percent and 4 percent for the year and includes earnings attributable to the firm's Apex Tool Group, which Danaher is in the process of divesting. Analysts, on average, expect EPS of $3.50 for FY 2013.

"In a low-growth global environment, the Danaher Business System continues to drive solid margin and cash flow performance across our business," Danaher President and CEO H. Lawrence Culp said in a statement. "We are focused on gaining on gaining market share while remaining active on the acquisition front."

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.